SG11201401605QA - Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof - Google Patents
Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereofInfo
- Publication number
- SG11201401605QA SG11201401605QA SG11201401605QA SG11201401605QA SG11201401605QA SG 11201401605Q A SG11201401605Q A SG 11201401605QA SG 11201401605Q A SG11201401605Q A SG 11201401605QA SG 11201401605Q A SG11201401605Q A SG 11201401605QA SG 11201401605Q A SG11201401605Q A SG 11201401605QA
- Authority
- SG
- Singapore
- Prior art keywords
- compositions
- methods
- alkaline phosphatase
- natriuretic peptide
- natriuretic
- Prior art date
Links
- 102000002260 Alkaline Phosphatase Human genes 0.000 title 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 title 1
- 108020001621 Natriuretic Peptide Proteins 0.000 title 1
- 102000004571 Natriuretic peptide Human genes 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000000692 natriuretic peptide Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/06—Anti-spasmodics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161549047P | 2011-10-19 | 2011-10-19 | |
| US201261649717P | 2012-05-21 | 2012-05-21 | |
| PCT/US2012/039004 WO2013058833A1 (en) | 2011-10-19 | 2012-05-22 | Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201401605QA true SG11201401605QA (en) | 2014-09-26 |
Family
ID=48141235
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201401605QA SG11201401605QA (en) | 2011-10-19 | 2012-05-22 | Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof |
Country Status (8)
| Country | Link |
|---|---|
| EP (2) | EP3488861B1 (enExample) |
| JP (1) | JP6118807B2 (enExample) |
| KR (1) | KR20140084201A (enExample) |
| CA (1) | CA2852874A1 (enExample) |
| ES (2) | ES2714406T3 (enExample) |
| HK (1) | HK1201446A1 (enExample) |
| SG (1) | SG11201401605QA (enExample) |
| WO (2) | WO2013058833A1 (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2887039T3 (es) | 2004-04-21 | 2021-12-21 | Alexion Pharma Inc | Conjugados para administración ósea y procedimiento de uso de estos para dirigir proteínas al hueso |
| WO2012088608A1 (en) | 2010-12-27 | 2012-07-05 | Enobia Canada Limited Partnership | Compositions comprising natriuretic peptides and methods of use thereof |
| US10052366B2 (en) | 2012-05-21 | 2018-08-21 | Alexion Pharmaceuticsl, Inc. | Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof |
| WO2016007873A1 (en) | 2014-07-11 | 2016-01-14 | The Regents Of The University Of Michigan | Compositions and methods for treating craniosynostosis |
| BR112017011900A2 (pt) | 2014-12-05 | 2018-02-27 | Alexion Pharma Inc | tratamento de ataques com fosfatase alcalina recombinante |
| CA2973883A1 (en) | 2015-01-28 | 2016-08-04 | Alexion Pharmaceuticals, Inc. | Methods of treating a subject with an alkaline phosphatase deficiency |
| JP6693134B2 (ja) * | 2015-02-02 | 2020-05-13 | 東ソー株式会社 | リンカー配列を有する抗体及びそれを用いた測定法 |
| CA2981103A1 (en) | 2015-03-31 | 2016-10-06 | Vhsquared Limited | Polypeptides |
| KR102789821B1 (ko) * | 2015-03-31 | 2025-04-02 | 소리소 파마슈티컬스 인크. | 프로테아제-절단가능 링커를 갖는 펩티드 구조물 |
| DK4089113T3 (da) | 2015-03-31 | 2024-02-05 | Sorriso Pharmaceuticals Inc | Polypeptider |
| DK3328416T5 (da) | 2015-07-30 | 2024-10-07 | Biomarin Pharm Inc | Anvendelse af natriuretske peptidvarianter af c-typen til behandling af skeletdysplasi |
| AU2016308624B2 (en) * | 2015-08-17 | 2022-06-23 | Alexion Pharmaceuticals, Inc. | Manufacturing of alkaline phosphatases |
| JP6868617B2 (ja) * | 2015-09-28 | 2021-05-12 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 低ホスファターゼ血症の組織非特異的アルカリホスファターゼ（ｔｎｓａｌｐ）酵素補充療法に有効な投薬計画の特定 |
| WO2017074466A1 (en) | 2015-10-30 | 2017-05-04 | Alexion Pharmaceuticals, Inc. | Methods for treating craniosynostosis in a patient |
| US11065306B2 (en) | 2016-03-08 | 2021-07-20 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia in children |
| WO2017173395A1 (en) | 2016-04-01 | 2017-10-05 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia in adolescents and adults |
| US11186832B2 (en) * | 2016-04-01 | 2021-11-30 | Alexion Pharmaceuticals, Inc. | Treating muscle weakness with alkaline phosphatases |
| US20190218274A1 (en) * | 2016-05-06 | 2019-07-18 | Phasebio Pharmaceuticals, Inc. | Elp fusion proteins for controlled and sustained release |
| US10988744B2 (en) | 2016-06-06 | 2021-04-27 | Alexion Pharmaceuticals, Inc. | Method of producing alkaline phosphatase |
| JP7018933B2 (ja) * | 2016-08-18 | 2022-02-14 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 気管気管支軟化症の治療方法 |
| EP3519438A1 (en) | 2016-09-30 | 2019-08-07 | VHsquared Limited | Compositions |
| TWI787230B (zh) | 2017-01-20 | 2022-12-21 | 法商賽諾菲公司 | 抗ＴＧＦ-β抗體及其用途 |
| TW202421659A (zh) * | 2017-01-20 | 2024-06-01 | 美商健臻公司 | 骨靶向抗體 |
| CN110719786A (zh) | 2017-03-31 | 2020-01-21 | 阿雷克森制药公司 | 用于治疗成人和青少年的低磷酸酯酶症(hpp)的方法 |
| US11338020B2 (en) | 2018-01-09 | 2022-05-24 | Synthetic Biologics, Inc. | Alkaline phosphatase agents for treatment of neurodevelopmental disorders |
| ES3032290T3 (en) | 2018-03-20 | 2025-07-16 | Theriva Biologics Inc | Intestinal alkaline phosphatase formulations |
| EP3773686B1 (en) | 2018-03-20 | 2023-06-07 | Theriva Biologics, Inc. | Alkaline phosphatase agents for treatment of radiation disorders |
| US11913039B2 (en) | 2018-03-30 | 2024-02-27 | Alexion Pharmaceuticals, Inc. | Method for producing recombinant alkaline phosphatase |
| EP3833377B1 (en) | 2018-08-10 | 2023-11-22 | Alexion Pharmaceuticals, Inc. | Bone healing at implants using alkaline phosphatase |
| CN113993541A (zh) | 2019-05-06 | 2022-01-28 | 合成生物制品有限公司 | 基于碱性磷酸酶的肿瘤学治疗 |
| AU2020296979A1 (en) | 2019-06-21 | 2022-02-24 | Sorriso Pharmaceuticals, Inc. | Polypeptides |
| EP3986571A1 (en) | 2019-06-21 | 2022-04-27 | Sorriso Pharmaceuticals, Inc. | Polypeptides |
| MX2022007114A (es) * | 2019-12-09 | 2022-07-11 | Alexion Pharma Inc | Polipeptidos de fosfatasa alcalina y metodos de uso de los mismos. |
| CN116848146A (zh) * | 2020-09-03 | 2023-10-03 | I·S·Y·陈 | 可溶性碱性磷酸酶构建体和包含编码可溶性碱性磷酸酶构建体的多核苷酸的表达载体 |
| BR112023016048A2 (pt) | 2021-02-12 | 2023-11-14 | Alexion Pharma Inc | Polipeptídeos de fosfatase alcalina e métodos de uso dos mesmos |
| AU2023232162A1 (en) * | 2022-03-11 | 2024-10-24 | Avirmax Biopharma Inc. | Compositions and methods for expressing therapeutics |
| WO2024094747A1 (en) | 2022-11-02 | 2024-05-10 | Novo Nordisk A/S | Cnp compounds |
| CN116286763B (zh) * | 2023-02-28 | 2024-06-25 | 西北工业大学 | 一种热稳定性提高的胱硫醚β-合成酶突变体及应用 |
| TW202513806A (zh) * | 2023-06-07 | 2025-04-01 | 美商拜奧馬林製藥公司 | 高通量篩選與身材矮小相關之基因變異體 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69108830T2 (de) | 1990-04-20 | 1995-09-14 | Hisayuki Matsuo | Neue im schwein vorkommende physiologisch aktive peptide. |
| JP3026351B2 (ja) | 1990-07-13 | 2000-03-27 | 壽之 松尾 | ブタｃｎｐ遺伝子及び前駆体蛋白 |
| JP2930380B2 (ja) | 1990-07-13 | 1999-08-03 | 壽之 松尾 | ブタ由来新規生理活性ペプチド（ｃｎｐ―５３） |
| JP3026354B2 (ja) | 1990-09-27 | 2000-03-27 | 壽之 松尾 | ヒトｃｎｐ遺伝子及び前駆体蛋白 |
| US5626863A (en) | 1992-02-28 | 1997-05-06 | Board Of Regents, The University Of Texas System | Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers |
| JP2809533B2 (ja) | 1991-01-31 | 1998-10-08 | 壽之 松尾 | Ｃｎｐ類似体ペプチド |
| WO1994020534A1 (en) | 1993-03-03 | 1994-09-15 | Mayo Foundation For Medical Education And Research | Vasonatrin peptide and analogs thereof |
| AU4255397A (en) | 1996-09-06 | 1998-03-26 | Trustees Of The University Of Pennsylvania, The | Chimpanzee adenovirus vectors |
| ATE360082T1 (de) | 1999-11-16 | 2007-05-15 | Genzyme Corp | Vektoren und transgene mit regulatorischen elementen zur genverabreichung in leber |
| US6407211B1 (en) | 1999-12-17 | 2002-06-18 | Mayo Foundation For Medical Education And Research | Chimeric natriuretic peptides |
| JP2002178279A (ja) | 2000-12-12 | 2002-06-25 | Ulvac Japan Ltd | 基板搬送方法 |
| IL142118A0 (en) * | 2001-03-20 | 2002-03-10 | Prochon Biotech Ltd | Method and composition for treatment of skeletal dysplasias |
| EP1395293B1 (en) | 2001-05-14 | 2009-07-22 | Gbp Ip, Llc | Lentiviral vectors encoding clotting factors for gene therapy |
| BRPI0203172B8 (pt) | 2001-09-28 | 2021-05-25 | Nakao Kazuwa | composição farmacêutica para acondroplasia |
| SG2013034475A (en) | 2001-11-21 | 2016-10-28 | Univ Pennsylvania | Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use |
| CA2433479A1 (en) | 2002-07-22 | 2004-01-22 | F. Hoffmann-La Roche Ag | Conjugate of a tissue non-specific alkaline phosphatase and dextran, process for its production and use thereof |
| ATE459370T1 (de) | 2002-11-26 | 2010-03-15 | Biocon Ltd | Modifizierte natriuretic verbindungen, konjugate und ihre verwendungen |
| WO2005007809A2 (en) | 2003-05-30 | 2005-01-27 | Alexion Pharmaceuticals, Inc. | Antibodies and fusion proteins that include engineered constant regions |
| JP4825667B2 (ja) | 2004-03-31 | 2011-11-30 | 一和 中尾 | 関節炎症治療剤又は予防剤 |
| WO2005094890A1 (ja) | 2004-03-31 | 2005-10-13 | Kazuwa Nakao | 身長増加用組成物 |
| JP2005292718A (ja) | 2004-04-05 | 2005-10-20 | Furukawa Electric Co Ltd:The | 光導波路、光導波路モジュールおよび光導波路の作成方法 |
| ES2887039T3 (es) | 2004-04-21 | 2021-12-21 | Alexion Pharma Inc | Conjugados para administración ósea y procedimiento de uso de estos para dirigir proteínas al hueso |
| US20070081984A1 (en) | 2005-10-11 | 2007-04-12 | Shunji Tomatsu | Compositions and methods for treating hypophosphatasia |
| CN101068575A (zh) | 2004-12-01 | 2007-11-07 | 建新公司 | 向肝脏定向递送遗传物质的方法 |
| TW200833840A (en) * | 2006-10-25 | 2008-08-16 | Amgen Inc | Toxin peptide therapeutic agents |
| US20080181903A1 (en) | 2006-12-21 | 2008-07-31 | Pdl Biopharma, Inc. | Conjugate of natriuretic peptide and antibody constant region |
| AU2008250945B2 (en) | 2007-05-11 | 2013-12-12 | Alexion Pharmaceuticals, Inc. | Bone targeted alkaline phosphatase, kits and methods of use thereof |
| US20100310561A1 (en) | 2007-06-06 | 2010-12-09 | Boehringer Ingelheim International Gmbh | Natriuretic fusion proteins |
| CA2693303C (en) | 2007-07-20 | 2017-11-07 | Mayo Foundation For Medical Education And Research | Natriuretic polypeptides |
| US20100184680A1 (en) * | 2007-09-11 | 2010-07-22 | Dorian Bevec | Therapeutic uses of b-type natriuretic peptide and human growth hormone 1-43 |
| EP2217620A2 (en) * | 2007-11-21 | 2010-08-18 | BioMarin Pharmaceutical Inc. | Variants of c-type natriuretic peptide |
| TWI471137B (zh) | 2009-05-20 | 2015-02-01 | Biomarin Pharm Inc | Ｃ型利鈉胜肽變異體 |
-
2012
- 2012-05-22 WO PCT/US2012/039004 patent/WO2013058833A1/en not_active Ceased
- 2012-05-22 KR KR1020147013214A patent/KR20140084201A/ko not_active Withdrawn
- 2012-05-22 SG SG11201401605QA patent/SG11201401605QA/en unknown
- 2012-05-22 CA CA2852874A patent/CA2852874A1/en not_active Abandoned
- 2012-10-18 ES ES12842640T patent/ES2714406T3/es active Active
- 2012-10-18 HK HK15101938.6A patent/HK1201446A1/xx unknown
- 2012-10-18 EP EP18201378.9A patent/EP3488861B1/en active Active
- 2012-10-18 WO PCT/US2012/060869 patent/WO2013059491A1/en not_active Ceased
- 2012-10-18 EP EP12842640.0A patent/EP2768526B1/en active Active
- 2012-10-18 ES ES18201378T patent/ES2944087T3/es active Active
- 2012-10-18 JP JP2014537254A patent/JP6118807B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ES2714406T3 (es) | 2019-05-28 |
| HK1201446A1 (en) | 2015-09-04 |
| ES2944087T3 (es) | 2023-06-19 |
| WO2013058833A8 (en) | 2013-06-13 |
| EP2768526A1 (en) | 2014-08-27 |
| CA2852874A1 (en) | 2013-04-25 |
| WO2013059491A1 (en) | 2013-04-25 |
| KR20140084201A (ko) | 2014-07-04 |
| JP6118807B2 (ja) | 2017-04-19 |
| WO2013058833A1 (en) | 2013-04-25 |
| EP2768526A4 (en) | 2015-04-15 |
| EP2768526B1 (en) | 2018-12-05 |
| EP3488861B1 (en) | 2023-02-15 |
| EP3488861A1 (en) | 2019-05-29 |
| JP2015502336A (ja) | 2015-01-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201401605QA (en) | Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof | |
| HUS2200031I1 (hu) | Anti-CGRP készítmények és alkalmazásuk | |
| EP2675471A4 (en) | HSA-RELATED COMPOSITIONS AND USE PROCESSES | |
| ZA201406250B (en) | Compositions of glp-1 peptides and preparation thereof | |
| IL232977B (en) | Intra-episode dexmedetomidine preparations and methods of using them | |
| PL2771071T3 (pl) | Kompozycje perfumeryjne i ich zastosowanie | |
| HUE041627T2 (hu) | Tisztító készítmények és eljárások | |
| EP2668044A4 (en) | COMPOSITIONS AND THEIR USE | |
| EP2750697A4 (en) | CHIMERIC NATRIURETIC PEPTIDE COMPOSITIONS AND METHOD FOR THE PRODUCTION THEREOF | |
| EP2741762A4 (en) | NATRIURETIC PEPTIDE COMPOSITIONS AND PREPARATION METHODS | |
| ZA201300041B (en) | Methods and compositions of beneficiation | |
| IL234228B (en) | Compositions of glp-1 peptides and preparation thereof | |
| HK1191055A (en) | Compositions comprising natriuretic peptides and methods of use thereof | |
| GB201120470D0 (en) | Compositions and uses thereof |